<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986440</url>
  </required_header>
  <id_info>
    <org_study_id>CS7017-A-E201</org_study_id>
    <nct_id>NCT00986440</nct_id>
  </id_info>
  <brief_title>Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy</brief_title>
  <official_title>A Randomized, Double-Blind Placebo-Controlled Phase 2 Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monotherapy treatment with CS-7017 to assess progression-free-survival (PFS) of subjects who
      achieved an objective response of Disease Control on first line therapy with Folinic acid
      (leucovorin), Fluorouracil (5-FU), Oxaliplatin (Eloxatin) known as FOLFOX; or Folinic acid
      (leucovorin), Fluorouracil (5-FU), irinotecan (Camptosar) known as FOLFIRI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare PFS rate of participants treated with CS-7017 versus placebo.</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare overall PFS of participants treated with CS-7017 versus placebo.</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare overall survival of participants treated with CS-7017 versus placebo.</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>CS-7017</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching CS-7017</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-7017</intervention_name>
    <description>CS-7017</description>
    <arm_group_label>CS-7017</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed, metastatic CRC that have achieved confirmed
             maximal benefit of DC following treatment with standard first line chemotherapy of a
             5-fluoropyrimidine plus either oxaliplatin or irinotecan. Patients should be entered
             onto this trial within 8 weeks of completing first line therapy;

          -  If CR was not achieved: measurable disease, i.e. at minimum one
             unidimensionally-measurable target lesion according to RECIST (Response Evaluation
             Criteria in Solid Tumors);

          -  Age &gt;= 18 years and Eastern Cooperative Oncology Group (ECOG) performance status (PS)
             =&lt; 2 at study entry;

          -  Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE,
             Version 3.0, grade =&lt; 1;

          -  Adequate organ and bone marrow function as evidenced by:

               -  Haemoglobin &gt;= 10 g/dL (transfusion and/or growth factor support allowed);

               -  Absolute neutrophil count (ANC) &gt;= 1.5 x 109/L;

               -  Platelet count &gt;= 100 x 109/L;

               -  Serum creatinine =&lt; 1.5 x ULN or creatinine clearance &gt;60 mL/min;

               -  AST and alkaline phosphatase &lt;2.5 x ULN if without liver metastasis and =&lt; 5.0 x
                  ULN if liver metastasis;

               -  Total bilirubin =&lt; 2.0 x ULN;

               -  Prothrombin time (PT)/International Normalised Ratio (INR) within normal limits
                  (WNL) unless therapeutically anticoagulated;

          -  Women of childbearing potential and men must be willing to consent to using highly
             effective methods of contraception (eg, hormonal contraceptives, bilateral tubal
             ligation, barrier with spermicide, intrauterine device) while on treatment and for at
             least 3 months thereafter;

          -  Males with the potential to father children must use two of the following methods of
             contraception acceptable for the study (e.g. hormonal contraceptives, bilateral tubal
             ligation, barrier with spermicide, intrauterine device) while on trial treatment and
             for at least 3 months thereafter.

          -  All female subjects of childbearing potential must have a negative pregnancy test
             (plasma or urine) result within 7 days before initiating study treatment;

          -  Baseline laboratory tests and tumor assessments must have been performed within 2
             weeks before initiating study treatment;

          -  Subjects must be fully informed about their illness and the investigational nature of
             the study protocol (including foreseeable risks and possible side effects) and must
             sign and date an IEC-approved ICF before performance of any study specific procedures
             or tests.

        Exclusion Criteria:

          -  Anticipation of need for a major surgical procedure or RT during the study;

          -  Treatment with chemotherapy, hormonal therapy, minor surgery, or any investigational
             agent within 4 weeks before study enrolment. Treatment with immunotherapy, biological
             therapy, or major surgery within 6 weeks before study enrolment. Treatment with RT
             within 1 week before study enrolment.

          -  History of any of the following conditions: diabetes mellitus requiring treatment with
             insulin or oral agents;

          -  Concomitant use of other TZDs;

          -  Myocardial infarction with significant impairment of cardiac function (e.g., ejection
             fraction =&lt; 50%); severe/unstable angina pectoris; coronary/peripheral artery bypass
             graft; congestive heart failure; cerebrovascular accident (CVA) or transient ischemic
             attack (TIA), pulmonary embolism, or other clinically significant thromboembolic
             event; clinically significant pulmonary disease (e.g., severe chronic obstructive
             pulmonary disease [COPD] or asthma);

          -  Brain metastasis; an uncontrolled seizure disorder; spinal cord compression; or
             carcinomatous meningitis;

          -  Pleural or pericardial effusion. Subjects with minimal pleural effusion may be
             eligible upon request by Investigator and approval by Sponsor;

          -  Clinically significant active infection that requires antibiotic therapy or Human
             Immunodeficiency Virus (HIV) positive subjects receiving antiretroviral therapy;

          -  Pregnant or breast feeding;

          -  Known history of severe hypersensitivity reactions to any of the components of CS 7017
             formulations;

          -  Serious intercurrent medical or psychiatric illnesses or any other conditions that in
             the opinion of the Investigator would impair the ability to give informed consent or
             unacceptably reduce protocol compliance or safety of the study treatment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fakulti nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Znojmo, p.o., Oddeleni radiacni a klinicke onkologie</name>
      <address>
        <city>Znojmo</city>
        <zip>66902</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux civils de colmar</name>
      <address>
        <city>Colmar</city>
        <state>Cedex</state>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <state>Cedex</state>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Medicale</name>
      <address>
        <city>Rennes</city>
        <state>Cedex</state>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Prive Saint Gregoire</name>
      <address>
        <city>Saint Grégoire</city>
        <zip>35768</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Donauwörth</name>
      <address>
        <city>Donauwörth</city>
        <zip>86609</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle Klinik und Poliklinik für Innere Medizin</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Cancer Research and Treatment - IRCC</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unita Operativa di Oncologia Medica</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Santa Maria alle Scotte</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie w Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VESALIUS Sp. z o.o.</name>
      <address>
        <city>Krakow</city>
        <zip>31-108</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ ONKOLOG s.c.</name>
      <address>
        <city>Warszawa</city>
        <zip>01-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Radiological Research Centre</name>
      <address>
        <city>Obninsk</city>
        <state>Kaluga</state>
        <zip>249030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan</state>
        <zip>4200111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Oncology Research Centre n.a. Blokhin, RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital #1</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NUZ Semashko Central Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Petersburg State Institution of Public Health</name>
      <address>
        <city>St Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution of Healthcare Clinical Hospital # 122 n.a.L.G Sokolov</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tula Regional Oncology dispensary</name>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Villaroel</state>
        <zip>170</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mútua de Terrassa</name>
      <address>
        <city>Terrassa (Barcelona)</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volyn regional oncology dispensary</name>
      <address>
        <city>Lutsk</city>
        <state>Volyn</state>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Oncology Hospital</name>
      <address>
        <city>Kiev</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sumy Regional Oncology Center</name>
      <address>
        <city>Sumy</city>
        <zip>40005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLH Cancer Clinical Trials Unit</name>
      <address>
        <city>London</city>
        <zip>NW1 2PQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efatutazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

